Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 827

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 827
---
 with the third party, under which the Company would receive a non -exclusivelicense to use stem cells for the production of a cell therapy for ALS. The license also included scientific research to be carried out in third -partyresearch laboratories.

Annex G-30 KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 17: — Contingent liabilities and COMMITMENTS (cont.) On March 24, 2020, the Company entered into an addendum to the agreement with the third party under which all the Company’s contracts became a non -exclusivelicense to use stem cells to create a cell therapy. In return, the rate of all royalties was reduced to 4% (compared to 5%) of product sales for a period of 15 years from the start of sales, and the payment for sublicenses was reduced to 15% (compared to 20%), provided that it does not fall below 1.25% of the sales. Since the Company has an agreement to pay royalties to an additional third party, in this case the royalty rates would be reduced from 4% to 2% of the product sales, and the payment for the sub -licenseswould be reduced to 10%. In addition, the Company would pay the aforementioned third party a payment for reaching milestones in the transplant product for the treatment of ALS according to the following rules: A.USD $150 thousand at the beginning of clinical phase IIb. B.USD $200 thousand at the beginning of clinical phase III. C.USD $2 million when obtaining a marketing license for a product to treat ALS in the US or Europe. In addition, the Company paid an annual license maintenance fee of USD $50 thousand until 2019, which was reduced to USD $30 thousand per year from 2020 and until 15 years pass from the current agreement’s execution. The annual license maintenance fees will be offset from the royalty payments. As of December 31, 2024, the Company does not have royalties liability. C.On August 31, 2009, the Company signed a license agreement with a third party, according to which the third party granted the Company a license to use the technology developed in exchange for the following payments: —An annual payment of USD $20 thousand, starting at the end of the fourth year from the date of signing the contract; —Milestone payments of up to USD $9,650 thousand; —Royalties at a rate of 3.